Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: Multiple mechanisms of action

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 3, 2007, Pages 892-901

  Hyeon, Ju Kim ^a   Rowe, Michael ^a   Ren, Ming ^a   Hong, Jau Shyong ^b   Chen, Po See ^b   Chuang, De Maw ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; HEAT SHOCK PROTEIN 70; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; PROTEIN P53; TRICHOSTATIN A; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN INFARCTION; BRAIN INJURY; CELL ACTIVATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; ISCHEMIA; MICROGLIA; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RAT; STROKE; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD11B; BRAIN; BRAIN ISCHEMIA; BUTYRATES; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; DISEASE MODELS, ANIMAL; ECTODYSPLASINS; ENZYME INHIBITORS; HISTONE DEACETYLASES; HISTONES; HSP70 HEAT-SHOCK PROTEINS; HYDROXAMIC ACIDS; MALE; MICROGLIA; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE II; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; TUMOR SUPPRESSOR PROTEIN P53; VALPROIC ACID;

EID: 34248530339     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.120188     Document Type: Article

References (39)

1. Bown CD, Wang JF, and Young LT (2000) Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells. Neuropharmacology 39:2162-2169.
2. Chen G, Zeng WZ, Yuan PX, Huang L-D, Jiang YM, Zhao ZH, and Manji HK (1999) The Mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 72:879-882.
3. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, Wilson B, Lu RB, Gean PW, Chuang DM, et al. (2006) Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 11:1116-1125.
4. Chuang DM, Hough C, and Senatorov VV (2005) Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative disease. Annu Rev Pharmacol Toxicol 45:269-290.
5. Doré S, Otsuka T, Mito T, Sugo N, Hand T, Wu L, Hurn PD, Traystman RJ, and Andreasson K (2003) Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol 54:155-162.
6. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, and Benz CC (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495-528.
7. Faraco G, Pancani T, Formentini L, Mascagni P, Fossati G, Leoni F, Moroni F, and Chiarugi A (2006) Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 70:1876-1884.
8. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23:9418-9427.
9. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, and Yamawaki S (2001) Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology 158:100-106.
10. Gregersen R, Lambertsen K, and Finsen B (2000) Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 20:53-65.
11. Gurvich N, Tsygankova OM, Meinkoth JL, and Klein PS (2004) Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64:1079-1086.
12. Hoehn B, Ringer TM, Xu L, Giffard RG, Sapolsky RM, Steinberg GK, and Yenari MA (2001) Overexpression of HSP72 after induction of experimental stroke protects neurons from ischemic damage. J Cereb Blood Flow Metab 21:1303-1309.
13. Huuskonen J, Suuronen T, Nuutinen T, Kyrylen S, and Salminen A (2004) Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. Br J Pharmacol 141:874-880.
14. Iadecola C and Gorelick PB (2005) The janus face of cyclooxygenase-2 in ischemic stroke shifting toward downstream targets. Stroke 36:182-185.
15. Iadecola C, Zhang F, Casey R, Nagayama M, and Ross ME (1997) Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 17:9157-9164.
16. Ichiyama T, Okada K, Lipton JM, Matsubara T, Hayashi T, and Furukawa S (2000) Sodium valproate inhibits production of TNF-α and IL-6 and activation of NF-kB. Brain Res 857:246-251.
17. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS, and Wu CW (2000) Histone deacetylase specifically down regulate p53 dependent gene activation. J Biol Chem 275:20436-20443.
18. Kanai H, Sawa A, Chen RW, Leeds P, and Chuang DM (2004) Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogen J 4:336-344.
19. Kim SF, Huri DA, and Snyder SH (2005) Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310:1966-1970.
20. Korzus E, Rosenfeld MG, and Mayford M (2004) CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42:961-972.
21. Langley B, Gensert JM, Beal MF, and Ratan RR (2005) Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord 4:41-50.
22. Leker RR, Aharonowiz M, Greig NH, and Ovadia H (2004) The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin α. Exp Neurol 187:478-486.
23. Leng Y and Chuang D-M (2006) Endogenous α-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 26:7502-7512.
24. Li Y, Chopp M, Chen J, Wang L, Gautam SC, Xu YX, and Zhang Z (2000) Intrastriatal transplantation of bone marrow nonhematopoietic cells improves functional recovery after stroke in adult mice. J Cereb Blood Flow Metab 20:1311-1319.
25. Lo EH, Dalkara T, and Moskowitz MA (2003) Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4:399-415.
26. Nogawa S, Forster C, Zhang F, Nagayama M, Ross ME, and Iadecola C (1998) Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc Natl Acad Sci USA 95:10966-10971.
27. Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, Yang S, and Hong JS (2005) Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Mol Brain Res 134:162-169.
28. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, and Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer and teratogen. J Biol Chem 276:36734-36741.
29. Rajdev S, Hara K, Kokubo Y, Mestril R, Dillmann W, Weinstein PR, and Sharp FR (2000) Mice overexpressing rat heat shock protein 70 are protected against cerebral infarction. Ann Neurol 47:782-791.
30. Ren M, Leng Y, Jeong MR, Leeds PR, and Chuang DM (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 89:1358-1367.
31. Ren M, Senatorov VV, Chen RW, and Chuang DM (2003) Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci USA 100:6210-6215.
32. Rogers DC, Campbell CA, Stretton JL, and Macky KB (1997) Correlation between motor impairment and infarct volume after permanent and transient middle cerebral artery occlusion in the rat. Stroke 28:2060-2066.
33. Ryu H, Lee J, Olofsson BA, Mwidau A, Dedeoglu A, Escudero M, Flemington E, Azizkhan-Clifford J, Ferrante RJ, and Ratan RR (2003) Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an SP1-dependent pathway. Proc Natl Acad Sci USA 100:4281-4286.
34. Stoll G, Jander S, and Schroeter M (1998) Inflammation and glial response in ischemic brain lesions. Prog Neurobiol 56:149-171.
35. Sugimoto K and Iadecola C (2003) Delayed effect of administration of COX-2 inhibitor in mice with acute cerebral ischemia. Brain Res 960:273-276.
36. Watanabe H, Ohta S, Kumon Y, Sakaki S, and Sakanaka M (1999) Increase in p53 protein expression following cortical infarction in the spontaneously hypertensive rat. Brain Res 837:38-45.
37. Yenari MA, Liu J, Zheng Z, Vexler JS, Lee JE, and Giffard RG (2005) Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection. Ann NY Acad Sci 1053:74-83.
38. Zhao H, Shimohata T, Wang JQ, Sun G, Schaal DW, Sapolsky RM, and Steinberg GK (2005) Akt contributes to neuroprotection by hypothermia against cerebral ischemia in rats. J Neurosci 25:9794-9806.
39. Zheng Z and Yenari MA (2004) Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurol Res 26:884-892.